This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

TZ101

Targazyme, Inc.

Drug Names(s): TZ-101 , TZ 101

Description: TZ101 is a enzyme-based treatment for use ex vivo in a variety of cell therapies. It is comprised of a recombinant enzyme, a-1,3 fucosyltransferase VI (FTVI), plus its substrate, GDP-fucose. TZ101 is designed to attach a sugar (fucose) to the surface of cells prior to administration of the cells to the patient.


TZ101 News

Pink Sheet Trademark Review


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug